On the Horizon in NSCLC: Antibody Drug Conjugates

Edward S. Kim, MD, MBA, and Alexander Spira, MD, PhD, FACP, provide an overview of antibody-drug conjugates, including mechanism of action, historical milestones in development, and the approved ADCs for non–small cell lung cancer treatment.

Alexander Spira, MD, PhD, FACP, and Edward S. Kim, MD, MBA, shift their focus to the use of antibody-drug conjugates in non-small cell lung cancer treatment with a review of ADC clinical trial data.

A discussion on how ADCs affect current standards of care in the non-small cell lung cancer treatment landscape.

Drs Edward S. Kim and Alexander Spira answer viewer questions on ADCs in non-small cell lung cancer.